Market Intelligence, Clinical Progress, and High-Purity Reagents for Epitranscriptomics and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for METTL14 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | METTL14 Recombinant Protein (or METTL3/METTL14 Complex) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for biophysical binding assays. |
View METTL14 Products |
| Gene Delivery | METTL14 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression validation. |
View METTL14 Products |
| Benchmark Ab | Anti-METTL14 Recombinant Antibody High-affinity positive control for Western Blot, IP, and IHC validation. |
View METTL14 Products |
| Validator | METTL14 siRNA Set Target-specific knockdown verification in functional phenotypic assays. |
View METTL14 Products |
| Related Target A | METTL3 The catalytic partner forming the stable m6A methyltransferase writer complex with METTL14. |
View METTL3 Products |
| Related Target B | FTO Key m6A demethylase (eraser) regulating the reversible epitranscriptomic machinery. |
View FTO Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting Active Complex | High-purity co-expressed METTL3/METTL14 heterodimer with verified stoichiometric ratio. |
| Selectivity Screening | Homolog panel including METTL16 and other methyltransferases verified by mass spectrometry. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and recombinant control proteins. |
| False Positives in RNA Binding | Endotoxin-controlled and RNase-free protein preparations to ensure assay integrity. |
Live METTL14 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for epitranscriptomic therapeutics is intensifying, with major players shifting focus from broad-spectrum epigenetic regulators to highly selective m6A writers and erasers. As first-generation METTL3 inhibitors reach early clinical phases, the next wave of R&D is targeting METTL14—either as an allosteric site to disrupt the heterodimer complex or as an RNA-binding scaffold to block substrate alignment. This strategy bypasses the highly conserved SAM-binding pocket, offering superior selectivity profiles.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Allosteric) | Storm Therapeutics, Accent Therapeutics | AML, Solid Tumors (GBM, HCC) | Protein-Protein Interaction (PPI) assays (Need high-purity METTL3/METTL14 complex) |
| PROTAC / Degrader | Academic Collaborations, Biotech Startups | Refractory Cancers | Ubiquitination & Degradation kinetics (Need lentivirus for stable reporter cell lines) |
| RNA-Targeting Small Mol | Gotham Therapeutics (Legacy/Pipeline) | Immuno-oncology | RNA-protein binding assays (Need RNase-free, sequence-verified METTL14 protein) |